NEW ORLEANS — Patients with intermediate dry age-related macular degeneration experienced meaningful improvement in visual acuity after treatment with risuteganib, according to a study.
“We’re treating patients 5 to 7 years before geographic atrophy,” Vicken Karageozian, MD, president and CEO of Allegro Ophthalmics, said in a presentation at the Eyecelerator meeting. “We have the potential to not only reverse vision loss, but also get functional vision back.”
Karageozian discussed data from a phase 2a study that compared risuteganib (Allegro) with sham in 39